1. Report Overview
1.1 Global Gene Therapy Market Overview
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to Gene Therapy
2.1 What is Gene Therapy?
2.2 Types of Gene Therapy
2.3 Products Excluded from the Report
2.4 Gene Therapy Vectors
3. Gene Therapy World Market: Leading Treatments and Forecasts, 2017-2028
3.1 The World Market for Gene Therapy: Overview of Products
3.2 Luxturna
3.3 Kymriah
3.4 Yescarta
3.5 Zolgensma
3.6 Gendicine (rAd-p53) - The First Gene Therapy to Market
3.7 Oncorine: Growth is Hindered by Certain Factors
3.8 Neovasculgen: Russia's First Gene Therapy
3.8.1 Neovasculgen: Historical Performance and Revenue Forecast, 2019-2030
3.9 Strimvelis: Second Gene Therapy for an Inherited Disease Ever to be approved for Sale and the First Corrective Gene Therapy for Children to be Approved Anywhere in the World
3.10 Glybera
4. Gene Therapy World Market: By Vector and Forecasts, 2020-2030
4.1 Viral Vectors
4.1.1 Retroviruses
4.1.2 Lentiviruses
4.1.3 Adenoviruses
4.1.4 Adeno Associated Virus
4.1.5 Herpes Simplex Virus
4.1.6 Poxvirus
4.1.7 Vaccinia Virus
4.2 Non-Viral Vector
4.2.1 Naked/Plasmid Vectors
4.2.2 Gene Gun
4.2.3 Electroporation
4.2.4 Lipofection
5. Gene Therapy World Market and Disease Submarkets, 2019-2030
5.1 The Global Market for Gene Therapy Drug Treatments in 2019
5.2 Gene Therapy Market Forecast, 2019-2030
5.3 Gene Therapy for Cancer
5.3.1 Clinical Trials for Cancer
5.3.2 The Cancer Gene Therapy Treatment Submarket Forecast 2019-2030
5.4 Gene Therapy for Rare Diseases
5.4.1 The Rare Disease Treatment Submarket Forecast 2019-2030
5.5 Gene Therapy for Cardiovascular Diseases
5.5.1 The Cardiovascular Disease Treatment Submarket Forecast 2019-2030
5.6 Gene Therapy for Ophthalmologic Diseases
5.6.1 Advanced Stage Gene Therapies for Ophthalmologic Diseases
5.6.2 The Ophthalmologic Disease Treatment Submarket Forecast 2019-2030
5.7 Gene Therapy for Infectious Diseases
5.7.1 Infectious Diseases Submarket Forecast 2019-2030
5.8 Gene Therapy for Neurological Disorders
5.8.1 Neurological Disorders Submarket Forecast 2019-2030
5.9 Gene Therapy for Diabetes Mellitus
5.9.1 Diabetes Mellitus Submarket Forecast 2019-2030
5.10 Gene Therapy for Other Diseases
5.10.1 The Other Disease Treatment Submarket Forecast 2019-2030
5.10.2 Changing Market Shares: Cancer Disease Gene Therapies Will Dominate and Become Market Leader
6. Gene Therapy World Market: by Region Forecasts, 2020-2030
6.1 Leading Regional Markets of Gene Therapy 2019-2030
6.2 North America
6.3 Europe
6.4 Asia Pacific
6.5 Latin America
6.6 MEA
7. R&D Pipeline Analysis and Forecasts, 2019-2030
7.1 Pipeline
7.2 Pipeline Analysis
7.3 Collategene (AMG0001) - AnGes MG/Vical
7.4 BC-819 - BioCancell
7.5 BC-821 - BioCancell
7.6 Lenti-D - Bluebird Bio
7.7 LentiGlobin (LentiGlobin BB305) - Bluebird Bio
7.8 SPK-CHM - Spark Therapeutics
7.9 SPK-FIX - Spark Therapeutics/Pfizer
7.10 SPK-TPP1- Spark Therapeutics
7.11 VM202-DPN - ViroMed
7.12 Important Pipeline Technology Developments
7.13 Clustered regularly interspaced short palindromic repeats (CRISPR)
7.14 The Future of the Gene Therapy Pipeline
8. Companies of Interest in the Gene Therapy Market: Robust Pipelines Will Yield Revenue in the Future
8.1 UniQure B. V. - the First Commercial Stage Gene Therapy Company in the West
8.2 Biogen - Focusing on Ophthalmologic and Rare Disease Gene Therapies
8.2.1 Biogen: Financial Performance 2015-2018
8.2.2 Biogen: Key News
8.3 Bluebird Bio: Gene Editing Technology
8.4 Spark Therapeutics- Strong Change to Become the First Company with Marketed Gene Therapy in the US
8.5 Applied Genetic Technologies Corporation: Specialisation in Ophthalmologic Diseases
8.6 Oxford Biomedica: Collaboration as a Strategy
8.7 GenSight Biologics - Novel Mitochondrial Technology Platform
8.8 Celgene Corporation
8.8.1 Celgene Corporation: Financial Overview
8.9 GlaxoSmithKline plc.
8.9.1 GlaxoSmithKline plc: Financial Overview
8.9.2 GlaxoSmithKline plc: Recent Transactions Summary
8.10 Takeda Pharmaceuticals
8.10.1 Takeda Pharmaceuticals: Financial Overview
8.10.2 Takeda Pharmaceuticals: Key News
8.11 Cellectis
8.11.1 Cellectis: Key News
8.12 Sangamo Therapeutics, Inc.
8.12.1 Sangamo Therapeutics, Inc: Key News
8.13 REGENXBIO Inc.
8.13.1 REGENXBIO Inc.: Key News
8.14 Voyager Therapeutics
8.14.1 Voyager Therapeutics: Key News
8.15 Bristol Myers Squibb
8.15.1 Bristol-Myers Squibb Company: Financial Overview
8.15.2 Bristol-Myers Squibb Company: Recent Transactions Summary
8.16 Genzyme Corporation
8.16.1 Genzyme Corporation: Key News
8.17 Chiesi Farmaceutici S.p.A
8.17.1 Chiesi Farmaceutici S.p.A: Key News
8.18 Benitec BioPharma
8.18.1 Benitec BioPharma: Key News
8.19 Gene Therapy and Big Pharma: Collaborations
9. Research Interviews
9.1 Kyriacos Mitrophanous, Chief Scientific Officer at Oxford Biomedica
9.1.1 Oxford Biomedica
9.1.2 Gene therapy landscape
9.1.3 Oxford Biomedica LentiVector ®
9.1.4 Pricing and Next Steps in Gene Therapy
9.2 Professor Dusko Ilic, Professor of Stem Cell Science, King's College London
9.2.1 Gene therapy landscape
9.2.2 Ethical Considerations with Gene Therapy
9.2.3 Regulation & Pricing of Gene Therapy Products
10. Qualitative Analysis of the Gene Therapy Market, 2020-2030
10.1 SWOT Analysis of the Gene Therapy Treatment Market, 2020
10.2 Strengths: A Vast Pipeline for a Wide Range of Indications
10.3 Weaknesses: Low Patient Populations Cannot Sustain Long-Term Growth
10.4 Opportunities and Threats for the Gene Therapy Drug Market, 2020-2030
10.5 Opportunities: Collaborations and Novel Technologies Will Pave the Way
10.6 Threats: Expensive Drugs with Strict Regulations
10.7 Regional markets: Regulation of the Gene Therapy Market
10.7.1 Gene Therapy Regulations: Evolving with the Market
10.7.2 US Regulations: Strict Regulation of a Cautious Market
10.7.3 EU Regulations: One Approval So Far
10.7.4 Japanese Regulations: A Rigorous Process
10.7.5 China Has Highest Gene Sequencing Capacity
11. Conclusions
11.1 The World Gene Therapy Treatment Market: Current World Outlook
11.1.1 Driver for Growth to 2030: A Vast Pipeline of Gene Therapy Products
11.1.2 Leading Gene Therapy Treatment Submarkets and Products, 2019-2030
11.1.3 Leading Regional Markets and Companies: Partnerships Will Achieve Success
11.2 The Future of the Gene Therapy Treatment Market
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Tables
Table 3.1 Approved Gene Therapies, 2019
Table 3.2 Luxturna Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.3 Kymriah Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.4 Yescarta Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.5 Zolgensma Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.6 Gendicine Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.7 Gene Therapies in Pipeline, 2019
Table 3.8 Oncorine Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.9 Neovasculgen Historical Revenue Comparisons, Revenue ($m), AGR (%), 2014-2018
Table 3.10 Neovasculgen Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.11 Strimvelis Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.1 Viral Vector Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.2 Retroviruses Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.3 Lentiviruses Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.4 Adenoviruses Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.5 Adeno Associated Virus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.6 Herpes Simplex Virus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.7 Poxvirus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.8 Vaccinia Virus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.9 Non-Viral Vector Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.10 Naked/Plasmid Vectors Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.11 Gene Gun Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.12 Electroporation Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.13 Lipofection Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 5.1 Leading Gene Therapy Drugs by Revenue ($bn), 2019
Table 5.2 World Market Forecasts for Gene Therapy Drugs by Indication, Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2019-2030
Table 5.3 Selected Anti-Angiogenic Gene Therapy Using a Non-Viral Vector, 2019
Table 5.4 Selected Anti-Angiogenic Gene Therapy Using a Retroviral Vector, 2019
Table 5.5 Selected Anti-Angiogenic Gene Therapy Using an Adenoviral Vector, 2019
Table 5.6 Selected Anti-Angiogenic Gene Therapy Using an Adeno-Associated Virus Vector, 2019
Table 5.7 Selected Anti-Angiogenic Gene Therapy Using Lentiviral Vector, 2019
Table 5.8 Global Gene Therapy Clinical Trials by Indication, 2019
Table 5.9 Selected Cancer Gene Therapies in Phase 2 and Phase 3 Clinical Trial Development, 2019
Table 5.10 Selected Cancer Gene Therapies in Phase 1 and Phase 1/2 Clinical Trial Development, 2019
Table 5.11 Global Gene Therapy Market: Revenue ($bn) and Market Shares (%) by Indication, 2019
Table 5.12 Global Market Forecast for Cancer Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
Table 5.13 Rare Diseases Gene Therapy Pipeline, 2019
Table 5.14 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
Table 5.15 Cardiovascular Gene Therapy Pipeline, 2019
Table 5.16 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
Table 5.17 Preclinical Ophthalmologic Pipeline, 2019
Table 5.18 Clinical Ophthalmologic Pipeline, 2019
Table 5.19 Additional Products in the Clinical Ophthalmologic Pipeline, 2019
Table 5.20 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
Table 5.21 Preclinical Infectious Diseases Pipeline, 2019
Table 5.22 Global Infectious Diseases Market Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
Table 5.23 Preclinical Neurological Disorders Pipeline, 2019
Table 5.24 Global Neurological Disorders Market Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
Table 5.25 Preclinical Diabetes Mellitus Pipeline, 2019
Table 5.26 Global Diabetes Mellitus Market Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
Table 5.27 Global Market Forecast for Other Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
Table 5.28 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2020-2025
Table 5.29 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2025-20230
Table 6.1 World Gene Therapy Market, by Region: Revenue ($Bn) and Market Share (%) 2019 and 2030
Table 6.2 Global Gene Therapy Market Forecast, by Region: Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 6.3 North America Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 6.4 Europe Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 6.5 Asia Pacific Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 6.6 Latin America Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 6.7 MEA Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 7.1 Promising Gene Therapies in Development, 2019
Table 7.2 Gene Therapies in Phase 3, 2019
Table 7.3 Collatagene Forecast, Revenue ($mn), AGR (%), CAGR (%), 2019-2030
Table 7.4 BC-819 Forecast, Revenue ($m), AGR (%), CAGR (%), 2019-2030
Table 7.5 Lenti-D Forecast, Revenue ($m), AGR (%), CAGR (%), 2019-2030
Table 8.1 UniQure B. V.: Overview, 2020
Table 8.2 uniQure Pipeline, 2020
Table 8.3 Biogen: Overview, 2020
Table 8.4 Bluebird Bio: Overview, 2020
Table 8.5 Spark Therapeutics: Overview, 2020
Table 8.6 Spark Therapeutics Collaborations, 2020
Table 8.7 Applied Genetic Technologies Corporation: Overview, 2020
Table 8.8 Oxford Biomedica: Overview, 2020
Table 8.9 Gensight Biologics: Overview, 2020
Table 8.10 Celgene Corporation: Overview, 2020
Table 8.11 GlaxoSmithKline plc: Overview, 2020
Table 8.12 Takeda Pharmaceuticals: Overview, 2019
Table 8.13 Cellectis: Overview, 2020
Table 8.14 Sangamo Therapeutics, Inc.: Overview, 2020
Table 8.15 REGENXBIO Inc.: Overview, 2020
Table 8.16 Voyager Therapeutics: Overview, 2020
Table 8.17 Bristol-Myers Squibb Company: Overview, 2020
Table 8.18 Genzyme Corporation: Overview, 2020
Table 8.19 Chiesi Farmaceutici S.p.A: Overview, 2020
Table 8.20 Benitec BioPharma: Overview, 2020
Table 8.21 Selected Big Pharma Collaborations in Gene Therapy, 2019
Table 9.1 Strengths and Weaknesses of the Gene Therapy Drug Treatment Market, 2020
Table 9.2 Gene Therapy Pipeline for Neurodegenerative Diseases, 2020
Table 9.3 Gene Therapy Pipeline for Metabolic Diseases, 2020
Table 9.4 Gene Therapy Pipeline for Musculoskeletal Diseases, 2020
Table 9.5 Gene Therapy Pipeline for Viral Diseases, 2020
Table 9.6 Opportunities and Threats of the Gene Therapy Drug Market, 2020
Table 9.7 Clinical Trials for Standard Drug Development Versus Orphan Drug Development, 2020
Table 10.1 World Gene Therapy Market, by Region: Revenue ($Bn) and Market Share (%) 2019 and 2030
List of Figures
Figure 1.1 Global Gene Therapy Market Segmentation Overview, 2020
Figure 2.1 Vectors Used in Gene Therapy Clinical Trials, 2019
Figure 3.1 Luxturna Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 3.2 Kymriah Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 3.3 Yescarta Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 3.4 Zolgensma Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 3.5 Gendicine Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 3.6 Oncorine Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 3.7 Neovasculgen Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 3.8 Strimvelis Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 4.1 Viral Vector Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 4.2 Retroviruses Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 4.3 Lentiviruses Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 4.4 Adenoviruses Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 4.5 Adeno Associated Virus Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 4.6 Herpes Simplex Virus Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 4.7 Poxvirus Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 4.8 Vaccinia Virus Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 4.9 Non-Viral Vector Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 4.10 Naked/Plasmid Vectors Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 4.11 Gene Gun Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 4.12 Electroporation Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 4.13 Lipofection Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 5.1 Gene Therapy World Market Forecast, Market Size ($bn), AGR (%), 2019-2030
Figure 5.2 Global Gene Therapy Clinical Trials by Indication, 2019
Figure 5.3 Cancer Gene Therapy Pipeline by Phase of Development, 2019
Figure 5.4 Global Gene Therapy Market: Market Shares (%) by Indication, 2019
Figure 5.5 Global Market Forecast for Cancer Gene Therapies: Revenue ($bn), 2019-2030
Figure 5.6 Rare Diseases Gene Therapy Pipeline by Phase of Development, 2020
Figure 5.7 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($bn), 2019-2030
Figure 5.8 Cardiovascular Gene Therapy Pipeline by Phase of Development, 2019
Figure 5.9 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($bn), 2019-2030
Figure 5.10 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($bn), 2019-2030
Figure 5.11 Global Infectious Diseases Market Forecast: Revenue ($bn), AGR (%), 2019-2030
Figure 5.12 Global Neurological Disorders Market Forecast: Revenue ($bn), AGR (%), 2019-2030
Figure 5.13 Global Diabetes Mellitus Market Forecast: Revenue ($bn), AGR (%), 2019-2030
Figure 5.14 Global Market Forecast for Other Disease Gene Therapies: Revenue ($bn), 2019-2030
Figure 5.15 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2025
Figure 5.16 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2028
Figure 6.1 Global Gene Therapy Market, by Region: Revenues (%), 2019
Figure 6.2 Global Gene Therapy Market, by Region: Revenues (%), 2025
Figure 6.3 Global Gene Therapy Market, by Region: Revenues (%), 2030
Figure 6.4 North America Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 6.5 Europe Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 6.6 Asia Pacific Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 6.7 Latin America Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 6.8 MEA Market Forecast, Revenue ($bn), AGR (%), 2019-2030
Figure 7.1 Gene Therapies in Clinical Development by Phase, 2019
Figure 7.2 Gene Therapy Market Strategy Analysis
Gene Therapy Market Strategy Analysis
Figure 7.3 Key Take Ways, Challenges and Application of CRISPR Market
Figure 7.4 Impact of CRISPR Technology on the Gene Therapy Market
Figure 8.1 Biogen: Revenue ($mn), 2015-2018
Figure 8.2 Celgene Corporation: Revenue ($mn), AGR (%), 2014-2018
Figure 8.3 Celgene Corporation: Regional Segment Revenue Share (%), 2018
Figure 8.4 GlaxoSmithKline plc: Revenue ($mn), 2014-2018
Figure 8.5 GlaxoSmithKline plc: Business Segment Revenue Share (%), 2018
Figure 8.6 GlaxoSmithKline plc: Pharmaceutical Business Segment Revenue Share (%), 2018
Figure 8.7 GlaxoSmithKline plc: by Region Revenue Share (%), 2018
Figure 8.8 Takeda Pharmaceuticals: Revenue ($bn), 2016-2018
Figure 8.9 Bristol-Myers Squibb Company: Revenue ($bn), AGR (%), 2014-2018
Figure 8.10 Bristol-Myers Squibb Company: Regional Segment Revenue Share (%), 2018
Figure 10.1 Gene Therapy Drug Treatment Market Forecast by Indication: Market Sizes ($bn), 2019, 2025, and 2030
